InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)

Revimmune0 个研究点目标入组 112 人开始时间: 2020年8月7日最近更新: 2023年9月26日

适应症

试验速览

暂无简介。

•1. A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation
•2. Men and women aged 25 - 80 (inclusive) years of age
•3. Hospitalized patients with two absolute lymphocyte count (ALC) =1000 cells/mm³, at two-time points at least 24 hours apart, following hospitalization. The first time point should not be performed earlier than 48 hours after hospitalization, thus first test dose can't be administered before 72 hours after hospitalization (From this time point the investigator may choose to further postpone the commencement of IL-7 (CYT107) treatment according to patient's clinical status)
•4. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4 l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g. BIPAP), or patients intubated/ventilated for respiratory failure
•5. Confirmed infection with COVID-19 by any acceptable test available/utilized at each site
•6. Private insurance or government support (through NHS or other)

•1. Pregnancy or breast feeding
•2. Refusal or inability to practice contraception regardless of the gender of the patient
•3. ALT and/or AST >5 x ULN
•4. Known, active auto-immune disease;
•5. Ongoing cancer treatment with chemotherapy/immunotherapy or any cancer therapy within the last 3 months and/or ongoing;
•6. Patients with past history of solid organ transplant.
•7. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load.
•8. Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours
•9. Patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day and/or anti-IL6 treatments like Tocilizumab or Sarilumab which should preferably be minimized
•10. Patients with baseline Rockwood Clinical Frailty Scale =6
•11. Patients under guardianship

发起方

Revimmune